Orchestra BioMed (NASDAQ:OBIO – Get Free Report) will likely be issuing its quarterly earnings data before the market opens ...

BTIG Research initiated coverage on shares of Orchestra BioMed (NASDAQ:OBIO – Free Report) in a report released on Thursday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $12.

BTIG analyst Marie Thibault initiated coverage of Orchestra BioMed (OBIO) with a Buy rating and $12 price target Orchestra is a medical ...

NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company ...

Orchestra BioMed Holdings, Inc. announced promising echocardiographic data regarding atrioventricular interval modulation (AVIM) therapy's impact on patients with diastolic dysfunction at the THT ...

Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development (“R&D”) collaborations aligned with Orchestra BioMed’s ...

Riley Securities Precision Oncology & RadioPharma Conference on February 28, 2025. Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to ...

Additionally, Orchestra BioMed will conduct one-on-one meetings with investors at the B. Riley Securities Precision Oncology & RadioPharma Conference on February 28, 2025. Engagement and Accessibility ...

Riley Securities Precision Oncology & RadioPharma Conference on February 28, 2025. Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients ...